Name of journal: *World Journal of Hepatology*

ESPS Manuscript NO: 13638

Columns: Topic Highlight

WJH 6th Anniversary Special Issues (3): Hepatitis B virus

**Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics**

Yano Y *et al*.Variations in HBV genome

Yoshihiko Yano, Takeshi Azuma, Yoshitake Hayashi

**Yoshihiko Yano, Yoshitake Hayashi,** Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kusunoki-cho, Kobe 650-0017, Japan

**Yoshihiko Yano, Takeshi Azuma,** Department of Gastroenterology, Kobe University Graduate School of Medicine, Kusunoki-cho, Kobe 650-0017, Japan

**Supported by** A Grant-in-Aid from the Japan Initiative for Global Research Network on Infectious Disease (J-GRID) Program of the Ministry of Education, Culture, Sports, Science and Technology, Japan; a SATREPS Grant from the Japan Science and Technology Agency and the Japan International Cooperation Agency; and by the Ministry of Health, Labour, and Welfare of Japan, No. H25-general-008

**Conflict-of-interest:** None.

**Open-Access:** This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Dr. Yoshihiko Yano, MD, PhD,** Center for Infectious Diseases, Graduate School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-Ku, Kobe 650-0017, Japan. yanoyo@med.kobe-u.ac.jp

**Telephone:** +81-78-3826305

**Fax:** +81-78-3826309

**Received:** August 28, 2014

**Peer-review started:** August 28, 2014

**First decision:** November 14, 2014

**Revised:** November 27, 2014

**Accepted:** December 29, 2014

**Article in press:**

**Published online:**

**Abstract**

Hepatitis B virus (HBV) infection is major global issue, because chronic HBV infection is strongly associated with liver cancer. HBV spread worldwide with various mutations and variations. This variability, called quasispecies, is derived from no proof-reading capacity of viral reverse transcriptase. So far, thousands of studies reported that the variety of genome is closely related to the geographic distribution and clinical characteristics. Recent technological advances including capillary sequencer and next generation sequencer have made in easier to analyze mutations. The variety of HBV genome is related to not only antigenicity of HBs-antigen but also resistance to antiviral therapies. Understanding of these variations is important for the development of diagnostic tools and the appropriate therapy for chronic hepatitis B. In this review, recent publications in relation to HBV mutations and variations are updated and summarized.

**Key words:** Hepatitis B virus; Mutation; Quasispecies

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis B virus (HBV) infection is major global issue. HBV spread worldwide with various mutations and variations. So far, thousands of studies reported that the variety of genome is closely related to the geographic distribution and clinical characteristics. Recent technological advances have made in easier to analyze mutations. Understanding of these variations is important for the development of diagnostic tools and the appropriate therapy for chronic hepatitis B.

Yano Y, Azuma T, Hayashi Y. Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics. *World J Hepatol* 2015; In press

**INTRODUCTION**

Hepatitis B virus (HBV) was first discovered by Blumberg *et al*[1] in 1965, and the relationship between HBV and acute hepatitis after blood transfusion was reported by Okochi in 1968[2]. At that time, most studies were based on immunological and serological methods. Molecular-based analyses progressed rapidly after the HBV particle was discovered[3] and the HBV genome cloned[4].

HBV infection is major global issue, and is a particular concern in Asia and Africa. Although HBV itself is not directly cytotoxic, the immune response to HBV infection causes liver damage and eventually leads to liver cirrhosis and hepatocellular carcinoma (HCC)[5]. More than 350 million people worldwide are thought to be chronically infected with HBV and 1–2 million people die every year from HBV-related cirrhosis and HCC[6]. The long-term outcomes of chronic hepatitis B (CHB) vary among different countries. The annual incidence of cirrhosis is estimated to range from 2% to 6% in hepatitis B e antigen (HBeAg)-positive patients and from 8% to 10% in HBeAg-negative patients. The annual incidence of HCC ranges from 2% to 3% in cirrhotic patients[7]. The goal of treating CHB is to suppress HBV replication before significant and irreversible liver damage occurs, such as end-stage decompensated cirrhosis and HCC. There are currently two main treatment options for chronic HBV infection, interferon (IFN) and nucleos(t)ide analogues.

**HBV GENOME AND REPLICATION**

HBV is approximately 42 nm in size. It is an incomplete double-stranded DNA virus from thegenus *Orthohepadnavirus* and family *Hepadnaviridae*. Its genome consists of full-length coding minus strand DNA and incomplete noncoding plus strand DNA. The viral particle, a Dane particle, comprises an envelope and a core particle (Figure 1A). The envelope is composed of a double lipid layer and three envelope proteins: L (large), M (medium), and S (small). The core particle (27 nm in size) consists of the core protein (HBc antigen) and the incomplete double-stranded DNA genome.

The HBV genome is contained within the capsid. It is approximately 3200 bp long, with four overlapping open reading frames (ORFs), which encode the polymerase (P), core (C), surface antigen (S), and X protein (Figure 1B)[8]. Seven viral proteins (HBeAg, HBcAg, LHBs, MHBs, SHBs, polymerase, and HBx) are produced from transcripts (Table 1).

The entry of HBV into human hepatocytes is the initial step of viral infection. It has been reported that the pre-S1 sequence at amino acids 2–48 mediates the attachment of the virus to its target cell[9]. After invading the target cells, HBV is transported to the nucleus where covalently closed circular DNA is constructed as the replication template of HBV.

Following infection, the HBV DNA is integrated into the host’s cellular DNA. HBV integration induces various kinds of secondary genetic alterations within the host’s genome, including deletions, translocations, and genomic instability[10]. It has been reported that the loss of chromosomal integrity in HCC is attributable to deletions in some chromosomes. In particular, losses in chromosomes 1p, 4q, 5q, 6q, 8p, 9p, 13q, 16p, 16q, and 17p have been detected in 25%-45% of patients, whereas gains occur in chromosomes 1p, 6p, 8q, and 17q in 30%-55% of patients[11].

Unlike other DNA viruses, reverse transcriptase is necessary for HBV replication. Because reverse transcriptase has no proof-reading capacity, DNA mutations frequently occur during replication. In general, the mutation rate of the hepadonaviruses is estimated to be 2 × 104 base substitutions/site/year. This mutation rate is approximately 100 times higher than that of other DNA viruses, but 100-1000 times lower than that of RNA viruses[12]. The mutation rate of HBV is reported to be in the range of 1.4-3.2 × 10−5 base substitutions/site/year[13].

Mutations and variations that occur naturally or during antiviral therapy play important roles in viral latency, the pathogenesis of liver disease, immune escape, and resistance to antiviral therapies.

**HBV GENOTYPES/SUBTYPES AND MUTATIONS**

The major hepatitis B s antigen (HBsAg) protein carries a pair of mutually exclusive determinants, d or y and w or r, which are associated with variations in single amino acids at positions 122 and 160, respectively. Differences in the epitope result in four major serotypes (adr, adw, ayr, and ayw) and ten subtypes (Figure 2)[14]. The serotypes and subtypes show differing geographic distributions and affect the antigenic characteristics of HBV[15,16].

HBV has been classified into at least 10 genotypes (A–J) according to the divergence of their viral DNA sequences, with distinct geographic distributions (Table 2)[17–19]. In addition, many studies have revealed that the HBV genotype is strongly associated with disease progression and responses to antiviral therapies[20,21].

HBV/A is mainly distributed in Africa (HBV/A1), the United States of America, and Europe (HBV/A2). Several reports from Africa, India, and Brazil have shown that HBV/A1 is associated with a high incidence of HCC in younger patients without cirrhosis[22]. By contrast, HBV/A2 is reported to be associated with a lower incidence of HCC than HBV/D and HBV/F[23,24]. HBV/A2 readily progresses to chronic infection after an acute infection, and is a major genotype in cases of vertical transmission[25]. HBV/B is mainly distributed in Asia, and is subclassified into HBV/B1/Bj and HBV/B2-5/Ba. HBV/B1 is found in Japan and is the most asymptomatic genotype. HBV/B2-5 is mainly detected in South-East Asia and has similar clinical characteristics to HBV/C. HBV/B and HBV/C are prevalent in the Far East and in South-East Asia. Several studies from Taiwan, Thailand, China, and Japan have shown that HBV/C is more aggressive and is associated with a greater risk of HCC than HBV/B[26-29]. HBV/D is detected worldwide, with HBV/D1 in Central Asia, HBV/D2 in Russia, HBV/D3 in Inner Mongolia, and HBV/D4 in Africa. HBV/D is reportedly associated with worse clinical outcomes than HBV/A[23,30].

The therapeutic efficacy of antiviral drugs is also related to the HBV genotype. HBV/A and HBV/B had better persistent response to IFN than HBV/C and HBV/D. A meta-analysis revealed that the response to IFN, including HBeAg seroconversion, loss of HBeAg and loss of HBV DNA, is better in HBV/A compared with HBV/D, and the response of HBV/B is better than that of HBV/C[31]. Whereas the HBeAg seroconversion rate by one-year treatment were respectively HBV/A 47%, HBV/B 44%, HBV/C 28%, and HBV/D 25%, HBsAg seroclearance rates were respectively HBV/A 14%, HBV/B 9%, HBV/C 3%, and HBV/D 2%[32]. It has also been reported that the HBs and HBe seroconversion rates are higher for HBV/A than for other genotypes[33]. A recent study reported that the response to IFN in HBV/E was worse than that in other genotypes[34]. However, the therapeutic responses to nucleotide analogue have been shown as mostly similar. Several meta-analyses revealed that HBV/B had no different response to lamivudine as HBV/C[35,36]. Though few studies were available, the therapeutic efficacy to other nucleos(t)ide analogues except lamivudine was same among genotypes[37]. It would be because the genomic variety in relation to antiviral resistance within polymerase region were mostly same among genotypes (Table 3).

**METHODS AVAILABLE FOR DETECTING MUTATIONS**

Recent technological advances have made it easier to detect mutations in HBV DNA. Several approaches can be used to detect HBV genomic mutations. Polymerase chain reaction (PCR) amplification with direct Sanger sequencing is perhaps the most commonly used method, but it cannot detect variations in < 20% of viral quasispecies. By contrast, line probe assays can detect specific variants occurring in > 5% of viral quasispecies[38,39]. Other highly sensitive methods include restriction fragment length polymorphism analysis[40], clone-based sequencing[41], and real-time PCR. More recently, several next-generation sequencing methods have been developed, including ultra-deep pyrosequencing, which can detect thousands of clonally amplified regions[42-45]. However, this method also has some limitations and it is unclear whether the variants found in different positions are actually located in the same clones because the next-generation sequencing read is shorter than the Sanger sequence read. Furthermore, it is still difficult to analyze insertion and deletion variants.

**CHARACTERISTICS OF THE *PRE-S/S* GENE**

The S ORF (nt 2854–835) encodes three different translated genes: pre-S1, pre-S2, and S domain. The pre-S domain is essential for viral binding to hepatocyte receptors and contains several epitopes that are targeted by T and B cells. The S domain is also important in the production of HBsAg[9]. There are three forms of HBV surface proteins (S, M, and L), of different sizes[46]. The 24-kDa S protein, which contains 226 amino acids, is the major component of the envelope protein and is involved in particle budding. The 33-kDa M protein contains the S protein and an additional 55 amino acids encoded by the *pre-S2* gene. Finally, the 39-kDa L protein contains the M protein and an additional 108 or 119 amino acids, the sequence of which depends on the genotype[47]. The three HBsAg types share a common region, consisting of the main antigenic loop (amino acids 124–147), which is called the “a” determinant region. The “a” determinant region is the main epitope to induce a protective immune response. It is located in the major hydrophilic region (MHR) of the S protein, which is between amino acids 103 and 173. The MHR forms a two-loop structure. Mutations and variations in the *S* gene have been reported in many countries[48]. Although these mutations occur naturally, they are also generated during immunoglobulin therapy or vaccine-induced immunity. Variations in the “a” determinant region cause changes in HBsAg antigenicity and may prevent the detection of HBsAg in HBsAg screening assays (Figure 3)[49,50]. These mutations also occur naturally in developing countries where nucleos(t)ide analogues are less frequently used than in developed countries[51,52].

HBsAg is an important diagnostic marker and its expression level is related to the efficacy of an antiviral treatment. Recent studies have revealed that the HBsAg titer correlates with the level of HBV DNA and hepatocarcinogenesis. However, mutations in the *pre-S/S* region are strongly related to HBs antigenicity, and it is reported that the presence of *pre-S/S* variants correlates negatively with the HBsAg titer[53]. Mutations in the S region result in antigenic variations and may allow HBV to escape vaccination. Such mutations are known as “vaccine escape mutations”. A study of HBsAg-negative patients from Hong Kong revealed that a variety of mutations, including deletions in the promoter region, abolition of the pre-S2/S start codon, disruption of the pre-S2/S mRNA splice site, nucleotide duplications, and missense mutations in the “a” determinant region, contribute to defects in HBsAg production (Table 4)[54].

The HBs antigen was discovered pathologically as ground glass hepatocytes (GGH) in 1973[55]. Different types of GGHs are associated with the expression patterns of surface/core antigens and the stage of virus replication. Type I GGHs express an inclusion-like pattern of HBsAg and carry mutants with deletions in the pre-S1 region. By contrast, type II GGHs are distributed in clusters, emerge in the late replicative phase, and contain mutants with deletions in the pre-S2 region. Because the pre-S2 region includes an epitope targeted by cytotoxic T lymphocytes, type II GGHs may represent an immune escape mutant[56]. It has also been reported that pre-S mutants could induce endoplasmic reticulum stress, followed by oxidative DNA damage and genomic instability[57,58]. Recent studies have also shown that the pre-S2 region upregulates human telomerase reverse transcriptase expression and transactivates forkhead box P3 expression, which may promote the development of HCC[59]. Clinical studies have revealed that pre-S deletions, pre-S2 start codon mutations, and the T53C mutation in the pre-S2 region are related to the development of HCC[60].

**CHARACTERISTICS OF THE *P* GENE**

The *P* gene encodes the 843-amino-acid virus-specific DNA polymerase and partially overlaps the other three genes. The DNA polymerase is located in the core of the virus. It acts as the DNA primer and exhibits reverse transcriptase, RNaseH, and DNA-dependent DNA polymerase activities.

A tyrosine (Y)–methionine (M)–aspartic acid (D)–aspartic acid (D) motif (YMDD) starting at codon 203 forms the enzyme activity center of the polymerase There are several well-known hot spots in the HBV DNA where mutations lead to the emergence of antiviral drug resistance. In particular, long-term treatment with lamivudine sometimes leads to the emergence of YMDD variants and breakthrough hepatitis[61]. Nucleos(t)ide analogues approved for the treatment of CHB include lamivudine, adefovir, entecavir, telbivudine, and tenofovir. Nucleos(t)ide analogues have a similar structure to natural nucleotides and compete with natural nucleotides for binding sites on the polymerase during DNA synthesis. Incorporation of nucleos(t)ide analogues instead of natural nucleotides disrupts DNA synthesis and suppresses viral replication.

M204M/I is a well-known mutation that confers resistance to l-nucleosides, including lamivudine and telbivudine. The M204V/I mutation is also associated with compensatory mutations, such as L80V/I, I169T, V173L, L180M, T184S/G, S202I, and Q215S[62]. Mutations A181T and N236T, which are located outside the YMDD motif, are major mutations that confer resistance to alkyl-phosphonates, such as adefovir and tenofovir[63]. The mutations T184G/S, S202I/G, and M250V in combination with L180M and M204V confer resistance to d-cyclopentanes, including entecavir (Table 4 and 5)[64].

The overlapping region of the *P* and *S* genes is important for drug resistance and HBs antigenicity (Table 3). A triple mutation in the P protein (V173L + L180M + M204V) is accompanied by a double mutation in the S protein (E164D + I195M). This mutant may confer antiviral resistance and promotes vaccine escape[65,66]. Furthermore, the introduction of an rtA181T (A181T in reverse transcriptase) surface nonsense mutation (rtA181T/sW172\*) reduced viral replication and increased drug resistance compared with the introduction of an rtA181T surface missense mutation (rtA181T/sW172S)[67].

**CHARACTERISTICS OF THE *X* GENE**

The X ORF (nt 1374–1838) encodes HBx, a 154-amino-acid 16.5 kDa protein. HBx is a multifunctional protein that modulates transcription, signal transduction, cell-cycle progression, protein degradation pathways, apoptosis, and genetic stability by interacting with a variety of host factors[68,69].

HBx protein is strongly associated with the development of HCC. HBx activates cAMP and several transcription factors, including nuclear factor κB and activating transcription factor 2. It also stimulates RAS, SRC, and c-JUN, resulting in activation of the RAS–RAF oncogenic pathways[70].

Deletion of the basal core promoter (BCP) causes a frame shift in the *X* gene, leading to the production of a truncated X protein. The truncated X protein is frequently detected in HCC, and is thought to contribute to hepatocarcinogenesis by upregulating *RAS* and *MYC*. Despite the deletions of nt 1637–1667, which regulate p53-dependent transcription, and nt 1733–1754, corresponding to the SP1-binding region in the CP domain, truncated X protein is still capable of regulating various transcription factors and competes with protein p53. Moreover, because amino-acid mutations at positions 130 and 131 of the X protein overlap the core promoter region, these mutations are associated with the progression of CHB and hepatocarcinogenesis.

Several mutations in the *X* gene are reported to be are associated with hepatocarcinogenesis. Liao *et al*[71] reviewed 85 case–control studies and reported that G1896A (OR = 1.46), G1899A (OR = 3.02), the pre-S1 deletion (OR = 2.94), and pre-S2 deletion (OR = 3.02) were significantly associated with the development of HCC. The A1762T/G1764A double mutant, T1753V and C1653T in the BCP were also associated with HCC. Similar results have reported in another meta-analysis of case–control studies[72], and several other mutations in the *X* gene are associated with hepatocarcinogenesis[73,74].

**CHARACTERISTICS OF THE PRE-CORE/CORE GENOME**

The pre-C/core region contains two regions; pre-C (nt 1814–1901) and core (nt 1901–2452). The core ORF encodes an 183-amino-acid core protein (HBcAg) and the pre-C ORF encodes the 29-amino-acid protein that connects to the N-terminal tail of the core protein. Although the *pre-C/C* gene produces HBcAg and HBeAg, only the cleaved form of HBeAg is released from infected cells into the blood, together with the HBV particle. Although the function of HBeAg is not completely understood, it may act as an immune “tolerogen”, contributing to the establishment of chronic infection[75].

The BCP and the adjacent pre-C region are crucial for the replication of HBV. The BCP binds to various liver factors and pre-C forms a pregenomic RNA structure that acts as the encapsidation signal[8]. Changes in viral replication may influence the progression of liver diseases[76]. In particular, nucleotide mutation G1896A, which replaces tryptophan (TGG) with a stop codon (TAG) at codon 28, is the most common and important factor responsible for the inhibition of HBeAg production[77,78].

A relatively common double mutation (A1762T and G1764A) in the BCP is responsible for reduced pre-C mRNA synthesis[79].

**CONCLUSION**

The treatment of CHB has changed dramatically in recent years. However, there is increasing evidence that viral variations and mutations that allow the virus to escape antiviral therapies are clinically important. HBV mutations are also closely related to the serological status of the patients. Understanding the viral mutations and their associations with the clinical characteristics of HBV infection should contribute to improvements in diagnostic procedures and therapeutic guidelines. Recent technological advances have made it easier to assess the HBV genome and detect possible variations or mutations in it. We believe it is important to discuss and implement generalized methods that are suitable for use worldwide.

**REFERENCES**

1 **Blumberg BS**, Alter HJ, Visnich S. A "new" antigen in leukemia sera. *JAMA* 1965; **191**: 541-546 [PMID: 14239025 DOI: 10.1001/jama.1965.03080070025007]

2 **Okochi K**, Murakami S. Observations on Australia antigen in Japanese. *Vox Sang* 1968; **15**: 374-385 [PMID: 5749015 DOI: 10.1111/j.1423-0410.1968.tb04078.x]

3 **Dane DS**, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. *Lancet* 1970; **1**: 695-698 [PMID: 4190997 DOI: 10.1016/S0140-6736(70)90926-8]

4 **Galibert F**, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. *Nature* 1979; **281**: 646-650 [PMID: 399327 DOI: 10.1038/281646a0]

5 **Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]

6 **Lee WM.** Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745 [PMID: 93927000 DOI: 10.1056/NEJM199712113372406]

7 **Fattovich G**, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; **127**: S35-S50 [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014]

8 **Seeger C**, Mason WS. Hepatitis B virus biology. *Microbiol Mol Biol Rev* 2000; **64**: 51-68 [PMID: 10704474 DOI: 10.1128/MMBR.64.1.51-68.2000]

9 **Glebe D,** Urban S, Knoop EV, Cag N, Krass P, Grün S, Bulavaite A, Sasnauskas K, Gerlich WH. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. *Gastroenterology* 2005; **129**: 234-245 [PMID: 16012950 DOI: 10.1053/j.gastro.2005.03.090]

10 **Bréchot C**. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 2004; **127**: S56-S61 [PMID: 15508104 DOI: 10.1053/j.gastro.2004.09.016]

11 **Zhang SH**, Cong WM, Xian ZH, Wu MC. Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China. *World J Gastroenterol* 2005; **11**: 3034-3039 [PMID: 15918185]

12 **Buti M**, Rodriguez-Frias F, Jardi R, Esteban R. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. *J Clin Virol* 2005; **34** Suppl 1: S79-S82 [PMID: 16461229 DOI: 10.1016/S1386-6532(05)80015-0]

13 **Orito E**, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. *Proc Natl Acad Sci U S A* 1989; **86**: 7059-7062 [PMID: 2780562 DOI: 10.1073/pnas.86.18.7059]

14 **Couroucé-Pauty AM**, Plançon A, Soulier JP. Distribution of HBsAg subtypes in the world. *Vox Sang* 1983; **44**: 197-211 [PMID: 6845678 DOI: 10.1111/j.1423-0410.1983.tb01885.x]

15 **Le Bouvier GL**, McCollum RW, Hierholzer WJ, Irwin GR, Krugman S, Giles JP. Subtypes of Australia antigen and hepatitis-B virus. *JAMA* 1972; **222**: 928-930 [PMID: 4120331 DOI: 10.1001/jama.1972.03210080020005]

16 **Norder H**, Couroucé AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. *J Gen Virol* 1992; **73** (Pt 12): 3141-3145 [PMID: 1469353 DOI: 10.1099/0022-1317-73-12-3141]

17 **Norder H**, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; **47**: 289-309 [PMID: 15564741 DOI: 10.1159/000080872]

18 **McMahon BJ**. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. *Hepatol Int* 2009; **3**: 334-342 [PMID: 19669359 DOI: 10.1007/s12072-008-9112-z]

19 **Kurbanov F**, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatol Res* 2010; **40**: 14-30 [PMID: 20156297 DOI: 10.1111/j.1872-034X.2009.00601.x]

20 **Kao JH**, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000; **118**: 554-559 [PMID: 10702206 DOI: 10.1016/S0016-5085(00)70261-7]

21 **Kramvis A**, Kew M, François G. Hepatitis B virus genotypes. *Vaccine* 2005; **23**: 2409-2423 [PMID: 15752827 DOI: 10.1016/j.vaccine.2004.10.045]

22 **Kew MC**, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. *J Med Virol* 2005; **75**: 513-521 [PMID: 15714494 DOI: 10.1002/jmv.20311]

23 **Sánchez-Tapias JM**, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002; **123**: 1848-1856 [PMID: 12454842 DOI: 10.1053/gast.2002.37041]

24 **Livingston SE**, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, Snowball MM, Cagle HH, Williams JL, Chulanov VP. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. *J Infect Dis* 2007; **195**: 5-11 [PMID: 17152003 DOI: 10.1086/509894]

25 **Matsuura K**, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* 2009; **47**: 1476-1483 [PMID: 19297602 DOI: 10.1128/JCM.02081-08]

26 **Lee CM**, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC, Chen WJ. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. *Scand J Gastroenterol* 2003; **38**: 95-101 [PMID: 12608471 DOI: 10.1080/00365520310000500]

27 **Tangkijvanich P**, Mahachai V, Komolmit P, Fongsarun J, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. *World J Gastroenterol* 2005; **11**: 2238-2243 [PMID: 15818732]

28 **Orito E**, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 2001; **33**: 218-223 [PMID: 11124839 DOI: 10.1053/jhep.2001.20532]

29 **Zhang AM**, Wang HF, Wang HB, Hu JH, He WP, Su HB, Chen J, Du N, Duan XZ. [Association between HBV genotype and chronic/severe liver disease with HBV infection in Chinese patients]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2010; **24**: 178-180 [PMID: 21186519]

30 **Thakur V**, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. *J Gastroenterol Hepatol* 2002; **17**: 165-170 [PMID: 11966946 DOI: 10.1046/j.1440-1746.2002.02605.x]

31 **Wiegand J**, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. *Antivir Ther* 2008; **13**: 211-220 [PMID: 18505172]

32 **Buster EH**, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology* 2008; **135**: 459-467 [PMID: 18585385 DOI: 10.1053/j.gastro.2008.05.031]

33 **Boglione L**, Cusato J, Cariti G, Di Perri G, D'Avolio A. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. *J Infect* 2014; **69**: 81-87 [PMID: 24631900 DOI: 10.1016/j.jinf.2014.02.018]

34 **Chen XL**, Li M, Zhang XL. HBV genotype B/C and response to lamivudine therapy: a systematic review. *Biomed Res Int* 2013; **2013**: 672614 [PMID: 24364035 DOI: 10.1155/2013/672614]

35 **Palumbo E**. Hepatitis B genotypes and response to antiviral therapy: a review. *Am J Ther* 2007; **14**: 306-309 [PMID: 17515708 DOI: 10.1097/01.pap.0000249927.67907.eb]

36 **Enomoto M**, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. *Clin Lab* 2006; **52**: 43-47 [PMID: 16506363]

37 **Wen Z**, Zhang H, Zhang M, Tan D, Li Q, Zhang H, Wu P, Deng L. Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. *Hepat Mon* 2014; **14**: e10813 [PMID: 25237370 DOI: 10.5812/hepatmon.10813]

38 **Cheng Y**, Guindon S, Rodrigo A, Wee LY, Inoue M, Thompson AJ, Locarnini S, Lim SG. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. *Gut* 2013; **62**: 1347-1355 [PMID: 23242209 DOI: 10.1136/gutjnl-2012-302408]

39 **Ghabeshi S**, Sharifi Z, Hosseini SM, Mahmoodian Shooshtari M. Correlation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutations. *Hepat Mon* 2013; **13**: e7415 [PMID: 23599717 DOI: 10.5812/hepatmon.7415]

40 **Mizokami M**, Nakano T, Orito E, Tanaka Y, Sakugawa H, Mukaide M, Robertson BH. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. *FEBS Lett* 1999; **450**: 66-71 [PMID: 10350059 DOI: 10.1016/S0014-5793(99)00471-8]

41 **Chen L**, Zheng CX, Lin MH, Huang ZX, Chen RH, Li QG, Li Q, Chen P. Distinct quasispecies characteristics and positive selection within precore/core gene in hepatitis B virus HBV associated acute-on-chronic liver failure. *J Gastroenterol Hepatol* 2013; **28**: 1040-1046 [PMID: 23278564 DOI: 10.1111/jgh.12109]

42 **Mardis ER**. Next-generation DNA sequencing methods. *Annu Rev Genomics Hum Genet* 2008; **9**: 387-402 [PMID: 18576944 DOI: 10.1146/annurev.genom.9.081307.164359]

43 **Astrovskaya I**, Tork B, Mangul S, Westbrooks K, Măndoiu I, Balfe P, Zelikovsky A. Inferring viral quasispecies spectra from 454 pyrosequencing reads. *BMC Bioinformatics* 2011; **12** Suppl 6: S1 [PMID: 21989211 DOI: 10.1186/1471-2105-12-S6-S1]

44 **Lin KT**, Shann YJ, Chau GY, Hsu CN, Huang CY. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing. *Oncogene* 2014; **33**: 4786-4794 [PMID: 24141781]

45 **Gong L**, Han Y, Chen L, Liu F, Hao P, Sheng J, Li XH, Yu DM, Gong QM, Tian F, Guo XK, Zhang XX. Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. *J Clin Microbiol* 2013; **51**: 4087-4094 [PMID: 24088859 DOI: 10.1128/JCM.01723-13]

46 **Schmitt S**, Glebe D, Alving K, Tolle TK, Linder M, Geyer H, Linder D, Peter-Katalinic J, Gerlich WH, Geyer R. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. *J Biol Chem* 1999; **274**: 11945-11957 [PMID: 10207016 DOI: 10.1074/jbc.274.17.11945]

47 **Ni Y**, Sonnabend J, Seitz S, Urban S. The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. *J Virol* 2010; **84**: 3879-3888 [PMID: 20130049 DOI: 10.1128/JVI.02528-09]

48 **Sayiner AA**, Ozcan A, Sengonul A. Naturally occurring MHR variants in Turkish patients infected with hepatitis B virus. *J Med Virol* 2008; **80**: 405-410 [PMID: 18205223 DOI: 10.1002/jmv.21104]

49 **Carman WF,** Mimms LT. Pre-S/S gene variants of hepatitis B virus. Rizetto M, Purcell RH, Gerin JL, Verne G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica, 1997: 108-115

50 **Melegari M**, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. *Virology* 1994; **199**: 292-300 [PMID: 8122362 DOI: 10.1006/viro.1994.1127]

51 **Pourkarim MR**, Sharifi Z, Soleimani A, Amini-Bavil-Olyaee S, Elsadek Fakhr A, Sijmons S, Vercauteren J, Karimi G, Lemey P, Maes P, Alavian SM, Van Ranst M. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: a nationwide study. *J Med Virol* 2014; **86**: 144-155 [PMID: 24150816 DOI: 10.1002/jmv.23798]

52 **Suwannakarn K**, Tangkijvanich P, Thawornsuk N, Theamboonlers A, Tharmaphornpilas P, Yoocharoen P, Chongsrisawat V, Poovorawan Y. Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. *Hepatol Res* 2008; **38**: 244-251 [PMID: 17711443 DOI: 10.1111/j.1872-034X.2007.00254.x]

53 **Pollicino T**, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, Squadrito G, Raimondo G. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. *Hepatology* 2012; **56**: 434-443 [PMID: 22271491 DOI: 10.1002/hep.25592]

54 **Huang FY,** Wong DK, Seto WK, Zhang AY, Lee CK, Lin CK, Fung J, Lai CL, Yuen MF. Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. *PLoS One* 2014; **9**: e99028 [PMID: 24901840 DOI: 10.1371/journal.pone.0099028]

55 **Hadziyannis S**, Gerber MA, Vissoulis C, Popper H. Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes of carriers. *Arch Pathol* 1973; **96**: 327-330 [PMID: 4582440]

56 **Wang HC**, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. *Am J Pathol* 2003; **163**: 2441-2449 [PMID: 14633616 DOI: 10.1016/S0002-9440(10)63599-7]

57 **Hsieh YH**, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis* 2004; **25**: 2023-2032 [PMID: 15180947 DOI: 10.1093/carcin/bgh207]

58 **Pollicino T**, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. *J Hepatol* 2014; **61**: 408-417 [PMID: 24801416 DOI: 10.1016/j.jhep.2014.04.041]

59 **Zhang X,** Gao L, Liang X, Guo M, Wang R, Pan Y, Liu P, Zhang F, Guo C, Zhu F, Qu C, Ma C. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. *Liver Int* 2014 Jul 22; Epub ahead of print [PMID: 25047684 DOI: 10.1111/liv.12642]

60 **Qu LS**, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. *PLoS One* 2014; **9**: e98257 [PMID: 24849936 DOI: 10.1371/journal.pone.0098257]

61 **Liaw YF**, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *Gastroenterology* 2000; **119**: 172-180 [PMID: 10889166 DOI: 10.1053/gast.2000.8559]

62 **Bartholomeusz A**, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. *Semin Liver Dis* 2006; **26**: 162-170 [PMID: 16673294 DOI: 10.1055/s-2006-939758]

63 **Borroto-Esoda K**, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. *J Hepatol* 2007; **47**: 492-498 [PMID: 17692425 DOI: 10.1016/j.jhep.2007.06.011]

64 **Zoulim F**, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology* 2009; **137**: 1593-1608.e1-2 [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063]

65 **Torresi J**, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. *Virology* 2002; **299**: 88-99 [PMID: 12167344 DOI: 10.1006/viro.2002.1448]

66 **Villet S**, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. *Gastroenterology* 2006; **131**: 1253-1261 [PMID: 17030194 DOI: 10.1053/j.gastro.2006.08.013]

67 **Ahn SH**, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK, Kwon SY, Kim KH. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. *J Virol* 2014; **88**: 6805-6818 [PMID: 24696492 DOI: 10.1128/JVI.00635-14]

68 **Pang R**, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. *Cancer Lett* 2006; **240**: 157-169 [PMID: 16239065 DOI: 10.1016/j.canlet.2005.08.031]

69 **Tang H**, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. *Cancer Sci* 2006; **97**: 977-983 [PMID: 16984372 DOI: 10.1111/j.1349-7006.2006.00299.x]

70 **Benn J**, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. *Proc Natl Acad Sci U S A* 1994; **91**: 10350-10354 [PMID: 7937954 DOI: 10.1073/pnas.91.22.10350]

71 **Liao Y**, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. *PLoS One* 2012; **7**: e38394 [PMID: 22675557 DOI: 10.1371/journal.pone.0038394]

72 **Liu S**, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. *J Natl Cancer Inst* 2009; **101**: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]

73 **Madden CR**, Finegold MJ, Slagle BL. Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. *J Virol* 2001; **75**: 3851-3858 [PMID: 11264374 DOI: 10.1128/JVI.75.8.3851-3858.2001]

74 **Sirma H**, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Bréchot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. *Oncogene* 1999; **18**: 4848-4859 [PMID: 10490818 DOI: 10.1038/sj.onc.1202867]

75 **Yang CY**, Kuo TH, Ting LP. Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response. *J Biol Chem* 2006; **281**: 34525-34536 [PMID: 16973626 DOI: 10.1074/jbc.M510981200]

76 **Jammeh S**, Tavner F, Watson R, Thomas HC, Karayiannis P. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. *J Gen Virol* 2008; **89**: 901-909 [PMID: 18343830 DOI: 10.1099/vir.0.83468-0]

77 **Carman WF**, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. *Lancet* 1989; **2**: 588-591 [PMID: 2570285 DOI: 10.1016/S0140-6736(89)90713-7]

78 **Omata M**, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N Engl J Med* 1991; **324**: 1699-1704 [PMID: 2034246 DOI: 10.1056/NEJM199106133242404]

79 **Li J**, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. *J Virol* 1999; **73**: 1239-1244 [PMID: 9882327]

**P-Reviewer:** Al-Shamma S, Amarapurkar DN, Betrosian AP, El-Bendary

**S-Editor:** Tian YL **L-Editor: E-Editor:**

**Table 1 Position of hepatitis B virus regions and transcripts**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ORF**  | **Protein** | **Position** | **Amino acids** | **Protein** |
| *Pre-S/S* | Pre-S1 | 2854–3211 | 119 | LHBs |
| Pre-S2 | 3211–155 | 55 | MHBs/LHBs |
| S | 155–835 | 226 | SHBs/MHBs/LHBs |
| *P* | P | 2357–1623 | 843 | Polymerase |
| *X* | X | 1374–1838 | 154 | HBxAg |
| *Pre-C/C* | Pre-C | 1814–1901 | 29 | HBeAg, HBcAg |
| C | 1901–2458 | 183 |  |

ORF: Open reading frame; S: Surface protein; LHBs: Hepatitis B large surface protein; MHBs: Hepatitis B medium surface protein; SHBs: Hepatitis B small surface protein; P: Polymerase; HBxAg: Hepatitis B X antigen; C: Core; HBeAg: Hepatitis B e antigen; HBcAg: Hepatitis B c antigen.

**Table 2 Hepatitis B virus** **subtypes and genotypes and their geographic distributions**

|  |  |
| --- | --- |
| **Genotype/****subgenotype** | **Geographic location** |
| A A1 A2 A3 | Saharan Africa, IndiaNorthern EuropeWestern Africa |
| B B1 (Bj) B2–5 B6 | JapanEast and Southeast AsiaAlaska, Northern Canada |
| C C1–3 C4 C5 | Taiwan, China, Korea, Southeast AsiaAustraliaPhilippines, Vietnam |
| D D1–5 | Africa, Europe, Mediterranean countries and India |
| E | West Africa |
| F | Central and South America |
| G | France, Germany, United States |
| H | Central America |
| I | Vietnam and Laos |
| J | Ryukyu, Japan (Kalimantan) |

**Table 3 Nucleotide alignment of polymerase region among different genotypes**



**1**Indicated the known antiviral resistant against nucleos(t)ide analogue.

**Table 4 Representative mutations and clinical characteristics**

|  |  |  |
| --- | --- | --- |
| **Region** | **Mutation** | **Clinical characteristics** |
| *Pre-S/S* | P120S/E,K122R,T126A,P127T, Q129H/R,L134S,K141E,P142S, D144A/E/V,G145R/A | OBI/HBsAg decrease |
| Pre-S deletion | HCC |
| *Pre-C/C* | A1896T, G1899A | HBe seroconversionHCC |
| *X* | C1653T, T1753C, A1762T, G1764A | HCC |
| *P* | L180M,A181V,T184G,S202I,M204V/IN236T,M250V | NA resistance |

S: Surface; OBI: Occult hepatitis B virus infection; HCC: Hepatocellular carcinoma; HBe: Hepatitis B e; HBsAg: Hepatitis B s antigen.

**Table 5 Mutations associated with resistance to nucleos(t)ide analogues**

|  |  |
| --- | --- |
| **Nucleos(t)ide analogue** | **Resistance-conferring mutations** |
| Lamivudine | I169T, V173L, L180M, T184G, S202G, M204V/I, M250V |
| Adefovir | A181V/T, N236T |
| Entecavir | I169T, V173L, L180M, T184G, S202G, M204V/I, M250V |
| Telbivudine | I169T, V173L, L180M, T184G, S202G, M204V/I, M250V |
| Tenofovir | N236T |



**Figure 1 Structures of the HBV virus (Dane particle) and genome.** aa: Amino acids; C: Core; DS: Double-stranded; LHBs: Hepatitis B large surface protein; HBV: Hepatitis B virus; MHBs: Hepatitis B medium surface protein; P: Polymerase; SHBs: Hepatitis B small surface protein; HBcAg: Hepatitis B c antigen.



**Figure 2 Algorithms for determining hepatitis B virus subtype from the primary structure of the *S* gene.**



**Figure 3 Structures of the overlapping *P* and *S* genes.** HBsAg: Hepatitis B s antigen; P: Polymerase; S: Surface.